Abstract Number: 1334 • 2018 ACR/ARHP Annual Meeting
Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Low density granulocytes (LDGs) are a subset of neutrophils that spontaneously produce neutrophil extracellular traps (NETs) and type I IFN. The latter correlates with…Abstract Number: 1338 • 2018 ACR/ARHP Annual Meeting
Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
Validation of the diagnostic accuracy of myositis-related antibodies in a large patient-cohortLackner, A; Tiefenthaler, V; Mirzayeva, J; Graninger, W; Stradner, MH Background/Purpose: Myositis-specific antibodies (MSA) and…Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…Abstract Number: 2286 • 2018 ACR/ARHP Annual Meeting
Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
Background/Purpose: To assess the prevalence of myofascial inflammatory lesions visible by magnetic resonance imaging (MRI) and their changes after tocilizumab therapy in active polymyalgia rheumatica…Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…Abstract Number: 5L • 2017 ACR/ARHP Annual Meeting
Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI
Background/Purpose: Inclusion body Myositis (IBM) is the most frequent myositis in patients over 50 years old. Conventional immunosuppressive drugs are today ineffective or even aggravate…Abstract Number: 2137 • 2017 ACR/ARHP Annual Meeting
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, autoimmune chronic muscle diseases of childhood with significant potential long-term morbidity. In this study we investigate associations…Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…Abstract Number: 2166 • 2017 ACR/ARHP Annual Meeting
Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
Background/Purpose: Despite the absence of specific guidelines or trials on intravenous immunoglobulins (IvIg) in patients with idiopathic inflammatory myopathies (IIM), the treatment is considered effective…Abstract Number: 2309 • 2016 ACR/ARHP Annual Meeting
Focal Myositis: New Insights on Diagnosis and Pathology
Background/Purpose: Due to the rarity of the entity, the literature on focal myositis (FM) fails to address important questions on its nosology, associated disorders, clinical…Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…Abstract Number: 302 • 2015 ACR/ARHP Annual Meeting
Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis
Background/Purpose: Sporadic Inclusion Body Myositis (sIBM) is a progressive, idiopathic inflammatory myopathy characterized by dysphagia, weakness of proximal and distal muscles and atrophy. This cross-sectional…